Novel drugs approved by the EMA, the FDA and the MHRA in 2024: a year in review

Topouzis, S., Papapetropoulos, A., Alexander, S. P. H., Cortese-Krott, M., Kendall, D. A., Martemyanov, K., Mauro, C., Nagercoil, N., Panettieri, R. A., Patel, H. H., Schulz, R., Stefanska, B., Stephens, G. J. ORCID: https://orcid.org/0000-0002-8966-4238, Teixeira, M. M., Vergnolle, N., Wang, X. and Ferdinandy, P. (2025) Novel drugs approved by the EMA, the FDA and the MHRA in 2024: a year in review. British Journal of Pharmacology. ISSN 0007-1188 doi: 10.1111/bph.17458

Abstract/Summary

In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of 'orphan' drug authorisations in 2024 (21) is similar to that of 2023 (24), illustrating the dynamic development of therapeutics in areas of unmet need. The 2024 approvals of novel protein therapeutics (15) and advanced therapy medicinal products (ATMPs, 6) indicate a sustained trend also noticeable in the 2023 new drugs reviewed in this journal last year (16 and 11, respectively). Clearly, the most striking characteristic of the 2024 drug yield is the creative pharmacological design, which allows these medicines to employ a novel approach to target a disease. Some notable examples are the first drug successfully using a 'dock-and-block' mechanism of inhibition (zenocutuzumab), the first approved drug for schizophrenia designed as an agonist of M1/M4 muscarinic receptors (xanomeline), the first biparatopic antibody (zanidatamab), binding two distinct epitopes of the same molecule, the first haemophilia therapy that instead of relying on external supplementation of clotting factors, restores Factor Xa activity by inhibiting TFPI (marstacimab), or the first ever authorised direct telomerase inhibitor (imetelstat) that reprogrammes the oncogenic drive of tumour cells. In addition, an impressive percentage of novel drugs were first in class (28 out of 53 or 53% of the total) and a substantial number can be considered disease agnostic, indicating the possibility of future approved extensions of their use for additional indications. The 2024 harvest demonstrates the therapeutic potential of innovative pharmacological design, which allows the effective targeting of intractable disorders and addresses crucial, unmet therapeutic needs.

Item Type	Article
URI	https://reading-clone.eprints-hosting.org/id/eprint/121581
Item Type	Article
Refereed	No
Divisions	Interdisciplinary Research Centres (IDRCs) > Centre for Integrative Neuroscience and Neurodynamics (CINN) Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
Publisher	Wiley
Download/View statistics	View download statistics for this item